TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Trial details
- Registry ID
- NCT05456256
- Phase
- Phase 2
LTRN
Lantern Pharma Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256 | LTRN | Phase 2 | Recruiting | 2026-12Estimated |
Latest recorded trial changes
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
NCT05456256 · Lantern Pharma Inc.
Primary completion date changed
− Before
Dec 2025
+ After
Dec 2026